ORIC Pharmaceuticals, Inc.
ORIC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.31 | -0.46 | 0.19 | -0.96 |
| FCF Yield | -2.08% | -3.89% | -8.21% | -4.96% |
| EV / EBITDA | -31.03 | -19.99 | -11.79 | -14.45 |
| Quality | ||||
| ROIC | -8.92% | -11.65% | -14.12% | -15.32% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 50.00% |
| Cash Conversion Ratio | 0.77 | 0.85 | 1.09 | 0.77 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 19.83% | 5.20% | -15.07% | 3.22% |
| Safety | ||||
| Net Debt / EBITDA | 1.35 | 2.01 | 1.55 | 1.39 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -908.71 | -1,537.75 | -261.39 |